Integra Therapeutics Secures €10.5 Million from European Commission for FiCAT Advanced Therapies Platform

Integra Therapeutics, a biotech company specializing in gene writing tools, has been awarded a grant and equity investment totaling €10.5 …

Continue ›››

Brainomix and Boehringer Ingelheim Partner to Enhance Diagnosis and Treatment of Fibrosing Lung Disease

Brainomix, a leader in AI imaging solutions, has entered into a strategic partnership with Boehringer Ingelheim, a German pharmaceutical company, …

Continue ›››

Genentech Ends SHP2 Inhibitor Collaboration with Relay Therapeutics

Genentech, a member of the Roche Group, has decided to terminate its SHP2 inhibitor collaboration with Relay Therapeutics, returning the …

Continue ›››

CytoReason Secures $80 Million to Advance AI Disease Models

Technology-driven biotech startup CytoReason, a developer of computational disease models, has raised $80 million from a consortium of investors, including …

Continue ›››

Evaxion Biotech Showcases Enhanced AI-Immunology™ Capabilities at ISMB 2024

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has presented significant advancements in its AI-Immunology™ platform, specifically focusing on …

Continue ›››

Synchron Integrates Generative AI with Brain-Computer Interface Software

US-based brain-computer interface (BCI) company Synchron has integrated generative AI into its brain implant interface system, enhancing the ability of …

Continue ›››

Beyond Neuralink: The Diverse Landscape of Brain-Computer Interfaces

Brain-Computer Interfaces (BCIs) have captured the public imagination, largely due to high-profile projects like Neuralink from  Elon Musk's, who revealed …

Continue ›››

Oxford Drug Design Validates Novel Oncology Therapeutic Mechanism

Oxford Drug Design, an AI-driven drug discovery company, has achieved successful in vivo validation of its novel oncology therapeutic mechanism …

Continue ›››

Bioptimus Introduces H-optimus-0: An Open-Source AI Model for Pathology

French startup Bioptimus has released H-optimus-0, the largest open-source AI foundation model for pathology. With 1.1 billion parameters, this model …

Continue ›››

A Growing Race to Change Status Quo in the Lucrative NGS Market

Element Biosciences has raised over $277 million in a Series D funding round to further develop and commercialize its DNA …

Continue ›››

Gene-Editing Tool Modifies Gut Bacteria in Living Mice

Researchers have developed a new gene-editing tool capable of modifying bacterial populations within the gut microbiome of living mice. This …

Continue ›››

Lantern Pharma Advances Development of Molecular Diagnostic for Oncology Clinical Trials

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company, has reached a milestone in the development of a diagnostic tool for …

Continue ›››